GlassScriptPhysician profile
Jennifer M Schaeffer
NPI 1255608493
$7,818.71
in general payments reported to CMS, 2019-2025
51 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,893 · 2022: $1,396 · 2023: $1,772 · 2024: $1,348 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,189 · Education: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,189.11 |
| Education | $341.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $974.59 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $865.03 | 2021-2025 | |
| Abbvie INC. | $857.61 | 2021-2025 | |
| Astellas Pharma US INC | $713.50 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $650.64 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Glaxosmithkline, LLC. | $605.20 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $571.49 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $396.90 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Biohaven Pharmaceuticals, INC. | $221.25 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $171.68 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $149.33 | 2021-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $149.19 | 2023-2025 | Gemtesa |
| Corcept Therapeutics | $101.95 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $96.03 | 2024 | Cologuard Collection Kit |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Schaeffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.